Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis

被引:125
作者
Fluge, O. [1 ]
Gravdal, K. [2 ]
Carlsen, E. [3 ]
Vonen, B. [4 ]
Kjellevold, K. [5 ]
Refsum, S. [6 ]
Lilleng, R. [7 ]
Eide, T. J. [8 ]
Halvorsen, T. B. [9 ]
Tveit, K. M. [10 ]
Otte, A. P. [11 ]
Akslen, L. A. [2 ,12 ]
Dahl, O. [1 ,13 ]
机构
[1] Haukeland Hosp, Dept Oncol, N-5021 Bergen, Norway
[2] Haukeland Hosp, Dept Pathol, N-5021 Bergen, Norway
[3] Ullevaal Univ Hosp, Dept Surg, Oslo, Norway
[4] Univ No Norway, Dept Surg, Tromso, Norway
[5] Stavanger Univ Hosp, Dept Pathol, Stavanger, Norway
[6] Lab Pathol AS, Oslo, Norway
[7] Buskerud Cent Hosp, Dept Pathol, Drammen, Norway
[8] Univ Oslo, Natl Hosp, Dept Pathol, Oslo, Norway
[9] St Olavs Hosp, Dept Pathol, Trondheim, Norway
[10] Ullevaal Univ Hosp, Dept Oncol, Oslo, Norway
[11] Univ Amsterdam, Swammerdam Inst Life Sci, Dept Biochem, Amsterdam, Netherlands
[12] Univ Bergen, Gade Inst, Dept Pathol, Bergen, Norway
[13] Univ Bergen, Inst Med, Sect Oncol, Bergen, Norway
关键词
colorectal cancer; adjuvant chemotherapy; prediction of outcome; EZH2; ki-76; immunehistochemistry; TUMOR-CELL PROLIFERATION; ADJUVANT THERAPY; COLON-CANCER; BREAST-CANCER; STAGE-II; FLUOROURACIL; CHEMOTHERAPY; LEVAMISOLE; CARCINOMA; PROSTATE;
D O I
10.1038/sj.bjc.6605333
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND: Enhancer of zeste homologue 2 (EZH2) is a member of the Polycomb group of genes that is involved in epigenetic silencing and cell cycle regulation. METHODS: We studied EZH2 expression in 409 patients with colorectal cancer stages II and III. The patients were included in a randomised study, and treated with surgery alone or surgery followed by adjuvant chemotherapy. RESULTS: EZH2 expression was significantly related to increased tumour cell proliferation, as assessed by Ki-67 expression. In colon cancer, strong EZH2 expression (P = 0.041) and high proliferation (>= 40%; P = 0.001) were both associated with better relapse-free survival (RFS). In contrast, no such associations were found among rectal cancers. High Ki-67 staining was associated with improved RFS in colon cancer patients who received adjuvant chemotherapy (P 0.001), but not among those who were treated by surgery alone (P = 0.087). In colon cancers stage III, a significant association between RFS and randomisation group was found in patients with high proliferation (P = 0.046), but not in patients with low proliferation (P = 0.26). Multivariate analyses of colon cancers showed that stage III (hazard ratio (HR) 4.00) and high histological grade (HR 1.80) were independent predictors of reduced RFS, whereas high proliferation indicated improved RFS (HR 0.55). CONCLUSION: Strong EZH2 expression and high proliferation are associated features and both indicate improved RFS in colon cancer, but not so in rectal cancer. British Journal of Cancer ( 2009) 101, 1282-1289. doi:10.1038/sj.bjc.6605333 www.bjcancer.com Published online 22 September 2009 (C) 2009 Cancer Research UK
引用
收藏
页码:1282 / 1289
页数:8
相关论文
共 19 条
[1]   Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer:: A national cancer institute-national surgical adjuvant breast and bowel project collaborative study [J].
Allegra, CJ ;
Paik, S ;
Colangelo, LH ;
Parr, AL ;
Kirsch, I ;
Kim, G ;
Klein, P ;
Johnston, PG ;
Wolmark, N ;
Wieand, HS .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (02) :241-250
[2]   Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer [J].
Andre, T ;
Boni, C ;
Mounedji-Boudiaf, L ;
Navarro, M ;
Tabernero, J ;
Hickish, T ;
Topham, C ;
Zaninelli, M ;
Clingan, P ;
Bridgewater, J ;
Tabah-Fisch, I ;
de Gramont, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2343-2351
[3]   Proliferation is the strongest prognosticator in node-negative breast cancer: significance, error sources, alternatives and comparison with molecular prognostic markers [J].
Baak, Jan P. A. ;
Gudlaugsson, Einar ;
Skaland, Ivar ;
Guo, Lydia Hui Ru ;
Klos, Jan ;
Lende, Tone Hoel ;
Soiland, Havard ;
Janssen, Emiel A. M. ;
zur Hausen, Axel .
BREAST CANCER RESEARCH AND TREATMENT, 2009, 115 (02) :241-254
[4]   EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast [J].
Bachmann, IM ;
Halvorsen, OJ ;
Collett, K ;
Stefansson, IM ;
Straume, O ;
Haukaas, SA ;
Salvesen, HB ;
Otte, AP ;
Akslen, LA .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (02) :268-273
[5]   EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer [J].
Adrian P. Bracken ;
Diego Pasini ;
Maria Capra ;
Elena Prosperini ;
Elena Colli ;
Kristian Helin .
The EMBO Journal, 2003, 22 (20) :5323-5335
[6]   Ki67 protein: the immaculate deception? [J].
Brown, DC ;
Gatter, KC .
HISTOPATHOLOGY, 2002, 40 (01) :2-11
[7]   EZH2 promotes proliferation and invasiveness of prostate cancer cells [J].
Bryant, R. J. ;
Cross, N. A. ;
Eaton, C. L. ;
Hamdy, F. C. ;
Cunliffe, V. T. .
PROSTATE, 2007, 67 (05) :547-556
[8]   Cloning of a human homolog of the Drosophila Enhancer of zeste gene (EZH2) that maps to chromosome 21q22.2 [J].
Chen, HM ;
Rossier, C ;
Antonarakis, SE .
GENOMICS, 1996, 38 (01) :30-37
[9]   Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer [J].
Collett, K ;
Eide, GE ;
Arnes, J ;
Stefansson, IM ;
Eide, J ;
Braaten, A ;
Aas, T ;
Otte, AP ;
Akslen, LA .
CLINICAL CANCER RESEARCH, 2006, 12 (04) :1168-1174
[10]   Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group [J].
Dahl, Olav ;
Fluge, Oystein ;
Carlsen, Erik ;
Wiig, Johan N. ;
Myrvold, Helge E. ;
Vonen, Barthold ;
Podhorny, Nina ;
Bjerkeset, Ottar ;
Eide, Tor Jack ;
Halvorsen, Tore B. ;
Tveit, Kjell Magne .
ACTA ONCOLOGICA, 2009, 48 (03) :368-376